Zhang Xiaofang, Wei Kebo, Song Hongxia, Chen Xi, Yang Jiao, Zhao Jianmei, Jiang Yugu, He Xin
Department of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, China.
Department of Dermatology, Hospital of Chengdu University of TCM, Chengdu, Sichuan, China.
Front Med (Lausanne). 2025 Feb 25;12:1544197. doi: 10.3389/fmed.2025.1544197. eCollection 2025.
Pityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient's quality of life and is considered one of the intractable diseases in dermatology. Currently, no satisfactory clinical treatment options are available for this condition, presenting a considerable challenge for dermatologists. We conducted this systematic evaluation to assess the therapeutic potential of existing small molecule drugs for this disease.
To conduct a systematic review of the existing literature on the use of small molecule drugs for treating pityriasis rubra pilaris and to evaluate their clinical effectiveness and safety.
We conducted a systematic review of all the literature on small molecule drugs for the treatment of Pityriasis rubra pilaris and searched several databases until November 2024, including PubMed, Embase, Web of Science, and the Cochrane Library.
A total of 16 patients with pityriasis rubra pilaris from 11 publications were included. The small molecule drugs, including apremilast, upadacitinib, abrocitinib, and tofacitinib, demonstrate good efficacy and safety in the treatment of pityriasis rubra pilaris across all ages, particularly in patients who have failed systemic therapy and have a poor response to biological agents. However, the conclusions are limited by the small sample size and need to be further confirmed through large-scale randomized controlled clinical trials.
Small molecule drugs demonstrate favorable clinical efficacy and safety in the treatment of refractory pityriasis rubra pilaris, exhibiting a relatively rapid onset and a high safety profile. However, the findings in the literature may be affected by publication bias.
红皮病型毛发红糠疹是一种慢性、鳞屑性、角化性皮肤病，主要表现为鳞屑性斑块和角化性毛囊。这种疾病严重影响患者的生活质量，被认为是皮肤科的难治性疾病之一。目前，针对这种疾病尚无令人满意的临床治疗方案，给皮肤科医生带来了相当大的挑战。我们进行了这项系统评价，以评估现有小分子药物对该疾病的治疗潜力。
对现有的关于使用小分子药物治疗红皮病型毛发红糠疹的文献进行系统综述，并评估其临床有效性和安全性。
我们对所有关于小分子药物治疗红皮病型毛发红糠疹的文献进行了系统综述，并检索了多个数据库直至2024年11月，包括PubMed、Embase、科学网和考克兰图书馆。
纳入了来自11篇出版物的共16例红皮病型毛发红糠疹患者。小分子药物，包括阿普米司特、乌帕替尼、阿布昔替尼和托法替布，在治疗各年龄段的红皮病型毛发红糠疹中均显示出良好的疗效和安全性，尤其是在全身治疗失败且对生物制剂反应不佳的患者中。然而，这些结论受到样本量小的限制，需要通过大规模随机对照临床试验进一步证实。
小分子药物在治疗难治性红皮病型毛发红糠疹中显示出良好的临床疗效和安全性，起效相对较快且安全性高。然而，文献中的研究结果可能受到发表偏倚的影响。
